Farnesyl Transferase Inhibitors as a Novel Strategy for Targeting KRAS-Dependent Cancers

KRAS mutations drive tumorigenesis in multiple cancers, yet direct inhibitors display limited efficacy due to adaptive resistance. Recent preclinical findings indicate farnesyl transferase inhibitors (FTIs) can reduce compensatory mTOR and MAPK pathway activation. Evidence supports combining FTIs with KRAS inhibitors to enhance tumor suppression and delayed resistance.